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Loss-of-function diseases are often caused by destabilizing mutations that lead to protein misfolding and
degradation. Modulating the innate protein homeostasis (proteostasis) capacity may lead to rescue of
native folding of the mutated variants, thereby ameliorating the disease phenotype. In lysosomal storage dis-
orders (LSDs), a number of highly prevalent alleles have missense mutations that do not impair the enzyme’s
catalytic activity but destabilize its native structure, resulting in the degradation of the misfolded protein.
Enhancing the cellular folding capacity enables rescuing the native, biologically functional structure of
these unstable mutated enzymes. However, proteostasis modulators specific for the lysosomal system are
currently unknown. Here, we investigate the role of the transcription factor EB (TFEB), a master regulator
of lysosomal biogenesis and function, in modulating lysosomal proteostasis in LSDs. We show that TFEB
activation results in enhanced folding, trafficking and lysosomal activity of a severely destabilized glucocer-
ebrosidase (GC) variant associated with the development of Gaucher disease (GD), the most common LSD.
TFEB specifically induces the expression of GC and of key genes involved in folding and lysosomal traffick-
ing, thereby enhancing both the pool of mutated enzyme and its processing through the secretory pathway.
TFEB activation also rescues the activity of a b-hexosaminidase mutant associated with the development of
another LSD, Tay–Sachs disease, thus suggesting general applicability of TFEB-mediated proteostasis
modulation to rescue destabilizing mutations in LSDs. In summary, our findings identify TFEB as a specific
regulator of lysosomal proteostasis and suggest that TFEB may be used as a therapeutic target to rescue
enzyme homeostasis in LSDs.
INTRODUCTION
Lysosomal storage disorders (LSDs) are a group of inherited
metabolic diseases characterized by deficiencies in lysosomal
hydrolytic enzymes or accessory proteins and aberrant accu-
mulation of metabolites, including lipids and mucopolysac-
charides, in the lysosome (1). Gaucher disease (GD), the
most common among LSDs, is caused by loss of lysosomal
glucocerebrosidase (GC) activity and consequent accumula-
tion of its substrate, glucosylceramide (2). A number of muta-
tions in the gene encoding GC (GBA, NM_000157) have been
characterized (3). The most prevalent mutations in GD
patients consist of single amino acid substitutions that do not
impair the protein’s catalytic activity but destabilize the
protein’s native structure, resulting in extensive degradation
of the misfolded enzyme via ER-associated degradation
(ERAD) (4). Previous work has shown significant geno-
type–phenotype correlation in GD and suggested a direct cor-
relation between the extent of enzyme ERAD, lysosomal
trafficking and residual activity of mutated GC, and the sever-
ity of the clinical manifestations in GD patients (5). In fact, a
loss of lysosomal GC activity in GD patients was shown to
correlate with a decrease in the concentration of the mutated
enzyme due to ERAD and not with impaired enzyme activity
(6). Accordingly, most unstable GC variants containing mis-
folding mutations retain biologic activity if forced to fold
into their native 3D structure (7,8). On the other hand, overex-
pressing unstable GC variants did not result in properly folded,
∗To whom correspondence should be addressed at: CHBE-MS 362, 6100 Main St., Houston, TX 77005, USA. Tel: +1 7133483536;
Fax: +1 7133485478; Email: segatori@rice.edu
# The Author 2013. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Human Molecular Genetics, 2013 1–16
doi:10.1093/hmg/ddt052
 HMG Advance Access published February 18, 2013









functional enzymes (9), suggesting that the innate cell quality
control system cannot rescue severely destabilized GC var-
iants.
In an attempt to promote native folding, trafficking and ac-
tivity of mutated GC variants, considerable effort has recently
been devoted to modulate the proteostasis network in GD cells
(10). Specifically, a number of compounds have been reported
to function as proteostasis modulators in fibroblasts derived
from GD patients (11–16) and to enhance enzyme activity
of the most prevalent alleles: N370S GC, the enzyme variant
most frequently found in GD patients (4,17); and L444P
GC, the second most common allele, which is associated
with severe, presently incurable, neuropathic symptoms in
homozygous patients (18). Compounds reported to function
as proteostasis modulators in GD cells typically influence cel-
lular component or pathways that control protein folding and
degradation, including molecular chaperones, the ubiquitin–
proteasome system (12,19), Ca2+ homeostasis (14,15) and
ERAD (16). Specifically, we recently observed an increase
in L444P GC activity to about 30% of wild-type (wt) GC ac-
tivity in GD cells treated with modulators of Ca2+ homeostasis
(15) or with ERAD inhibitors (16). This rescue in the activity
increased to 40–50% of wt GC activity when these com-
pounds were used in combination with other proteostasis mod-
ulators (15). It is important to note that the abnormal storage of
glucosylceramide can be efficiently reduced by enhancing re-
sidual GC activity to as little as 20% of wt activity, which, in
turn, is expected to ameliorate GD symptoms (2).
We previously determined that these proteostasis modula-
tors, despite their diverse mechanisms of action, induce dra-
matic upregulation of GC transcription while promoting the
rescue of mutated GC folding and activity (12,14–16). We
speculated that upregulating GC expression while simultan-
eously enhancing the cellular folding and trafficking capacity
results in an increase of the natively folded mutated enzyme
that reaches the lysosome. In this study, we sought to identify
strategies to induce upregulation of GC expression and protein
processing through the secretory pathway, thereby establishing
the molecular basis for the development of proteostasis mod-
ulators that enhance GC activity for therapeutic intervention.
Recent studies suggest that a number of genes encoding
lysosomal proteins exhibit coordinated transcriptional behav-
ior and are regulated by the transcription factor EB (TFEB)
(20), which belongs to the MiT/TFE subfamily of helix–
loop–helix (bHLH) transcription factors (21). TFEB targets
share a common regulatory motif in their promoter regions,
namely the Coordinated Lysosomal Expression and Regula-
tion (CLEAR) element (GTCACGTGAC) (20). TFEB direct
targets have been identified by a combination of genomic
and transcriptomic approaches and include lysosomal hydro-
lases, lysosomal membrane proteins and proteins associated
with lysosomal biogenesis and autophagy (22). TFEB has
been shown to modulate lysosomal clearance by (i) regulating
the expression of hydrolytic enzymes in the lysosomes through
modulation of the CLEAR network (20); (ii) promoting lyso-
somal biogenesis and exocytosis through the regulation of pro-
teins involved in lysosomal protein trafficking (23) and (iii)
inducing autophagy (24). Interestingly, GBA, the gene encod-
ing GC, was shown to be a TFEB target (20). Here, we hy-
pothesize that TFEB is involved in the regulation of
lysosomal proteostasis. We tested this hypothesis by using
fibroblasts derived from GD patients with GC misfolding
mutations that result in low residual activity. We report that
TFEB-mediated activation of the CLEAR network rescues
lysosomal activity of a severely destabilized GC variant
(L444P GC) and identified LIMP2, a receptor for lysosomal
mannose-6-phosphate-independent targeting of GC to lyso-
somes (25), as a key player of the rescue process. We also
show that chemical activation of TFEB enhances the activity
of another GC variant (N370S GC) and of a b-hexosaminidase
mutant associated with the development of the neuropathic
LSD, Tay–Sachs disease, thus suggesting a general role for
TFEB in regulating processing and targeting of lysosomal
enzymes. In summary, our findings identify TFEB as a new
regulator of lysosomal proteostasis and suggest that TFEB
may be used as a therapeutic target to rescue enzyme homeo-
stasis in LSDs.
RESULTS
Chemical activation of TFEB enhances native folding,
trafficking and activity of L444P GC in GD patient-derived
fibroblasts
To investigate the role of TFEB in regulating lysosomal pro-
teostasis in LSDs, we first studied the effects of sucrose, a
known TFEB activator (20), in patient-derived fibroblasts har-
boring L444P GC. L444P GC is a severely destabilized
enzyme variant, which is typically targeted to ERAD leading
to almost complete loss of lysosomal GC activity (18).
L444P GC fibroblasts were cultured with a range of sucrose
concentrations for 8 days, and GC activity was measured
every 2 days using the intact cells activity assay as previously
described (14). L444P GC activity was observed to increase
4.4-fold in cells treated with 150 mM sucrose (final medium
concentration; P, 0.01) for 4 days compared with untreated
cells, which corresponds to 55% of the wt GC activity
(Fig. 1A). Prolonging the time of incubation with sucrose
resulted in even higher increase in GC activity, reaching
85% of wt GC activity after 8 days of treatment with
100 mM sucrose (P , 0.01).
Polyol osmolytes, such as sucrose, can act as chemical
chaperones and stabilize the protein native structure (26).
Particularly, sucrose was shown to promote native folding
and activity of denatured aminoacylase and prevent its ag-
gregation in vitro (27). Glycerol and glucose were also
reported to stabilize proteins prone to misfolding. Glycerol
treatment was shown to rescue the native conformation of
a severely destabilized variant of the cystic fibrosis trans-
membrane conductance regulator (F508 CFTR) and to
restore its function to a level comparable with wt CFTR in
NIH 3T3 cells (28). Glucose was shown to stabilize the
native state of purified wt transthyretin under denaturing
conditions or conditions inducing aggregation (29). To inves-
tigate whether the increase in L444P GC activity observed
upon sucrose treatment was due to sucrose function as a
chemical chaperone, we measured the activity of L444P
GC in cells treated with other known chemical chaperones,
glycerol and glucose (the latter being the degradation
product of sucrose) (26,29). L444P GC patient-derived
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fibroblasts were treated with glycerol or glucose under the
same conditions applied to test sucrose, and GC activities
were evaluated every 2 days for up to 8 days. We did not
observe any significant change in GC activity even after 8
days of treatment (Supplementary Material, Fig. S1), indicat-
ing that, unlike sucrose, glycerol and glucose do not promote
native folding of L444P GC. Together, these data suggest
that the main mechanism involved in sucrose-mediated
rescue of GC activity is likely not limited to its function
as a chemical chaperone or to the chaperone-like activities
of its breakdown product (i.e. glucose).
To investigate whether sucrose treatment enhances L444P
GC trafficking to the lysosome, we tested the glycosylation
state and subcellular localization of GC. GD fibroblasts were
treated with 150 mM sucrose for 4 days and L444P GC glyco-
sylation state was investigated by subjecting the total protein
content to endoglycosidase H (EndoH) treatment followed
by western blot analysis using a GC-specific antibody, as pre-
viously described (16). EndoH hydrolyzes immature high
mannose N-linked glycoproteins retained in the ER. EndoH
treatment typically leads to the detection of a low-molecular
weight (MW) band corresponding to partially glycosylated,
Figure 1. Sucrose treatment enhances L444P GC trafficking and activity in GD patient-derived fibroblasts. (A) Time course of relative L444P GC activities in
cells treated with a range of concentrations of sucrose for 8 days. GC activities were normalized to the activity of untreated cells (left y-axis) (P, 0.01). The
corresponding fraction of wt GC activity is reported (right y-axis). Data are reported as mean+SD (n ¼ 3). (B) Western blot analysis of the total protein content
from L444P GC fibroblasts treated with sucrose (150 mM for 4 days) and with EndoH, and detected using a GC antibody. The solid and dashed arrows indicate
EndoH-resistant and EndoH-sensitive bands, respectively. Quantification of GC bands was obtained with ImageJ analysis software. Quantification of the lower
MW, EndoH-sensitive band corresponding to ER-retained GC is reported in the white portion of the bars; quantification of higher MW, EndoH-resistant bands
corresponding to lysosomal GC is reported in the black portions. (C and D) Confocal microscopy analysis of GC and CNX (an ER marker) (C) and GC and
LAMP-1 (a lysosomal marker) (D) in L444P GC fibroblasts. Cells were treated with sucrose (150 mM) for 4 days. Colocalization of CNX (blue, column 1)
and GC (red, column 2) is indicated in purple (column 3) color. Colocalization of LAMP-1 (blue, column 1) and GC (red, column 2) is indicated in purple
(column 3) color. Heatmaps of co-localization images were obtained with ImageJ analysis software (column 4). Hot colors represent positive correlation
(co-localization), whereas cold colors represent negative correlation (exclusion). Unt, untreated; Suc, sucrose. The scale bar is 10 mm. (E) Annexin V
binding affinity change (%) in L444P GC patient-derived fibroblasts treated with sucrose (150 mM) or MG-132 (0.6 mM) for 16 h normalized to untreated
cells (P , 0.01). (F) PI binding population change (%) of cells treated with sucrose (150 mM) or MG-132 (0.6 mM) for 16 h normalized to untreated cells
(P , 0.01). The number of total counted cells was 10 000. The data are reported as the mean+SD (n ¼ 3).
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ER-retained GC (EndoH-sensitive) and a high-MW GC band
corresponding to fully glycosylated, lysosomal GC (EndoH-
resistant) in western blot experiments (30). A representative
western blot and the quantification of EndoH-resistant and
EndoH-sensitive GC bands are reported (Fig. 1B). In untreated
cells, nearly all L444P GC was detected as EndoH-sensitive at
0 h and 4 days, as expected (16). However, treatment with
sucrose for 4 days resulted in an increase of the GC EndoH-
resistant form up to 50% of the total GC protein, which also
increased by 8.5-fold (Fig. 1B). We also tested L444P GC sub-
cellular localization by confocal microscopy. L444P GC was
barely detectable in untreated cells due to extensive ERAD,
as expected (31), while a significantly larger pool of GC accu-
mulated both in the ER and in the lysosomes of cells treated
with 150 mM sucrose for 4 days (Fig. 1C and D). Together,
these results suggest that sucrose treatment promotes
rescue of L444P GC folding, resulting in GC escape of
ERAD, and increased lysosomal transport and enzymatic ac-
tivity (Fig. 1A).
A number of small molecule proteostasis modulators in-
cluding MG-132 (12) were reported to enhance L444P GC re-
sidual activity in patient-derived fibroblasts at the expense of
significant cytotoxicity and induction of apoptosis, most
likely due to activation of the unfolded protein response
(UPR) (14,16). To evaluate whether treatment with sucrose
affects cell viability under conditions promoting rescue of
mutated GC activity, we measured membrane rearrangement,
characteristic of early apoptosis (annexin V binding), and
membrane fragmentation, characteristic of late apoptosis (pro-
pidium iodide (PI) binding) using the Cyto-GLO
TM
annexin
V-FITC apoptosis detection kit as previously described (16).
MG-132 (0.6 mM) was used for comparison. Sucrose treatment
(150 mM, 4 days) did not cause any significant changes in ac-
tivation of apoptosis compared with untreated cells (Fig. 1E
and F).
Previous studies showed that TFEB localizes predominantly
in the cytoplasm in resting cells and translocates into the
nucleus upon activation under conditions of lysosomal stress
(20). Sucrose treatment, a model of lysosomal stress in cul-
tured cells (32), was shown to cause progressive nuclear trans-
location of TFEB in HeLa cells stably transfected for TFEB
expression (20). We asked whether sucrose treatment under
conditions that promote rescue of L444P GC activity
induces TFEB nuclear translocation. L444P GC fibroblasts
and wt fibroblasts were transfected with a plasmid encoding
TFEB fused to mRuby (23) and treated with sucrose
(150 mM). TFEB intracellular localization was evaluated
using confocal microscopy by monitoring the DAPI nuclear
stain and mRuby fluorescence (23) (Fig. 2A). As expected,
TFEB was barely detectable in the nucleus of untreated wt
cells (20). Partial nuclear translocation of TFEB was observed
in GD cells likely due to glucosylceramide-induced lysosomal
stress (20). Administration of sucrose resulted in an increase of
TFEB nuclear localization in both wt and GD fibroblasts
(Fig. 2A). TFEB nuclear localization in GD cells was quanti-
fied by calculating the fraction of transfected cells that present
nuclear localization of TFEB (Fig. 2B). TFEB nuclear local-
ization was observed in 31.3+ 2.3% of untreated L444P GC
fibroblasts transfected with TFEB-mRuby. The fraction of
cells presenting TFEB nuclear localization increased to
71.8+ 3.8% after 1 day and to 85.5+ 4.2% after 2 days of
treatment with sucrose (Fig. 2B; P, 0.01), demonstrating
that sucrose activates TFEB in GD fibroblasts.
Sucrose administration specifically activates the CLEAR
network in GD fibroblasts
To determine whether sucrose administration resulted in the
activation of the CLEAR network, and whether additional
transcriptional programs were also activated, we performed
expression microarray analysis of treated and untreated GD
fibroblasts and investigated global changes in gene expression.
We used the microarray platform HT-12 V4.0 (Illumina) to
profile the transcriptome changes in total RNA extracted
from GD fibroblasts before and after treatment with sucrose
for 4 days. After treatment, 925 genes were induced by a
fold change of at least 2. Gene Ontology (GO) and KEGG
pathway analysis of induced genes showed that the only sig-
nificantly over-represented class was related to lysosomal me-
tabolism (N ¼ 53; fold enrichment ¼ 5.4; adjusted P, 10220)
(Supplementary Material, Table S1). Comparison with
Figure 2. Sucrose treatment promotes TFEB nuclear localization in GD
patient-derived fibroblasts. (A) Confocal microscopy analysis of TFEB subcel-
lular localization in wt and L444P GC fibroblasts transfected with a plasmid
encoding mRuby-TFEB and treated with 150 mM sucrose for 24 h. Colocaliza-
tion of DAPI (blue, column 1) and mRuby-TFEB (red, column 2) is shown in
purple color (column 3). Heatmaps of co-localization images were obtained as
described in Figure 1. The scale bar is 5 mm. (B) Percentage of cells with
nuclear localization of mRuby-TFEB upon sucrose treatment. Representative
fields containing 50–100 cells were analyzed to calculate the percentage of
cells with mRuby-TFEB nuclear localization in cells that express
mRuby-TFEB (P , 0.01). Unt, untreated. Data are reported as mean+SD
(n ¼ 3).
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previous work (22) showed that most of these genes are part of
the CLEAR network and are, therefore, bona fide TFEB direct
targets (Fig. 3A). Additional TFEB targets of unknown func-
tion or not annotated as genes participating in the lysosomal
function were also induced by sucrose (Fig. 3A). No known
lysosomal gene was downregulated upon sucrose administra-
tion. A network analysis of upregulated genes performed
using coregulation analysis (22,33) and Cytoscape (34) for
graphical visualization showed that TFEB targets are located
at the core of the regulatory network formed by the genes
induced by sucrose (Fig. 3B). These data suggest that the
primary response of the cell to sucrose administration is the
activation of the CLEAR network through TFEB. Additional
induced genes that are not direct TFEB targets might be part
of secondary pathways that are activated following sucrose ad-
ministration or TFEB activation. However, no specific cellular
processes other than those related to lysosomal biogenesis and
function emerged from the analysis of induced genes.
Gene-set enrichment analysis (GSEA) is a statistically
powerful framework to analyze how a subset of genes of inter-
est is distributed in a set of differentially expressed genes (35).
GSEA ranks the list of differentially expressed genes from the
most upregulated to the most downregulated, without impos-
ing arbitrary thresholds (such as considering only genes with
a fold change greater than 2), and calculates an enrichment
score (ES, ranging from 21 to +1) that expresses the ten-
dency of the gene subset of interest to be upregulated (ES
between 0 and +1) or downregulated (ES between 21 and
0). GSEA of genes previously reported to be involved in lyso-
somal metabolism (20,22,36) showed that the vast majority of
these genes were induced by sucrose administration, resulting
in an ES of 0.62 (P , 0.0001) (Fig. 3C). Additional analysis
showed that 87% of TFEB targets that were differentially
expressed were upregulated by sucrose (ES ¼ 0.53; P,
0.0001) (Fig. 3D). The analysis of TFEB targets with a
known role in lysosomal functions showed an even more
skewed distribution, with 100% of these targets falling
within the group of upregulated genes and an ES of 0.66
(P , 0.0001) (Fig. 3E). Together, these data confirm that the
cell reacts to sucrose administration by activating TFEB,
which, in turn, induces its downstream targets and in particular
those involved in lysosomal functions.
To confirm these results, we measured the expression of
representative genes of the CLEAR network by Quantitative
RT–PCR (qRT–-PCR) at various time points of sucrose ad-
ministration. GD fibroblasts harboring the L444P GC allele
were treated with sucrose (150 mM; 2, 4 and 7 days). GBA
transcription was dramatically upregulated by sucrose treat-
ment (23- and 34-fold after 4 and 7 days of incubation, re-
spectively; Fig. 3F). The expression of the CLEAR genes,
HEXA (hexosaminidase A), TPP1 (tripeptidyl-peptidase 1),
LAMP1 (lysosome-associated membrane glycoprotein 1),
ATP6V1H (V-type proton ATPase subunit H), GRN (granulin)
and PSAP (proactivator polypeptide), was also significantly
upregulated by sucrose treatment (Fig. 3F and Supplementary
Material, Fig. S2). Additional expression analyses showed that
glycerol, a chemical chaperone that did not affect the activity
of L444P GC (Supplementary Material, Fig. S1A), caused
only minimal changes in the expression of genes of the
CLEAR network (Supplementary Material, Fig. S2). Together,
these data suggest a positive association among sucrose ad-
ministration, TFEB activation, induction of the CLEAR
network and rescue of L444P GC activity.
TFEB modulates L444P GC activity in patient-derived
GD fibroblasts
To directly assess the role of TFEB in the rescue of L444P GC
activity, we combined modulation of the levels of TFEB with
its activation via sucrose in L444P fibroblasts. We first trans-
fected L444P GC fibroblasts with a vector encoding TFEB and
measured GC activity with or without sucrose treatment.
Overexpression of TFEB resulted in a 2.4-fold increase in
L444P GC activity (30% of wt GC activity; Fig. 4A) com-
pared with the transfection control (cells transfected with the
empty vector, pcDNA4TM/TO). Sucrose treatment (150 mM,
4 days) in GD cells transfected with the empty vector resulted
in a 3.9-fold increase in L444P GC activity corresponding to
49% of wt GC activity (P , 0.01; Fig. 4A), which is consist-
ent with the results reported above (Fig. 1A). Interestingly, the
combination of sucrose administration and TFEB transfection
led to a higher increase in L444P GC activity than the two
treatments alone (5.7-fold increase compared with control
cells or 71% of wt GC activity; P, 0.01; Fig. 4A), suggesting
that the observed sucrose-mediated rescue of L444P GC activ-
ity depends on TFEB concentration. Wt fibroblasts were also
tested for comparison: while sucrose treatment increased GC
activity by 1.7-fold in wt fibroblasts and by 3.0-fold in wt
fibroblasts transfected with TFEB, TFEB overexpression
alone did not increase GC activity (Fig. 4B). The comparison
with results obtained in GD cells (Fig. 4A) suggests that TFEB
is not significantly activated in non-diseased cells, while it is at
least partially activated in GD cells, as previously shown in
cells derived from patients affected by other LSDs (20).
To test the hypothesis that TFEB activation is needed for
TFEB to promote rescue of L444P GC activity, GD fibroblasts
were transfected with two TFEB variants that localize prefer-
entially in the nucleus: TFEB containing a serine to alanine
substitution at position 124 (TFEB S142A), which inactivates
TFEB phosphorylation sites and promotes TFEB nuclear
translocation (24); and TFEB fused to a constitutive nuclear
localization signal, which forces TFEB to translocate into
the nucleus (TFEB-NLS-3xFLAG) (Supplementary Material,
Fig. S3). GC activities were found to increase 2.3-, 3.4- and
3.2-fold in GD fibroblasts transfected with wt TFEB, S142A
TFEB and TFEB-NLS, respectively (P, 0.05; Fig. 4C), there-
fore showing that changes in TFEB localization that mimic its
activation enhance the extent of L444P GC activity rescue.
Finally, small interfering RNA (siRNA) was used to silence
TFEB expression in cells treated with sucrose. TFEB silencing
resulted in 29–36% residual expression of TFEB compared
with cells transfected with a control siRNA (Fig. 4D), as eval-
uated by qRT–PCR. Accordingly, L444P GC activity
decreased from 3.9-fold in cells treated with sucrose and
control siRNA to 3.1-fold in cells treated with sucrose and
TFEB siRNA (P, 0.01; Fig. 4D). The residual increased
GC activity observed in TFEB-silenced cells was likely due
to sucrose-mediated activation of residual TFEB. Control
studies conducted using an siRNA that targets a different
portion of TFEB confirmed that silencing TFEB (29–40%
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Figure 3. Sucrose induces upregulation of the CLEAR network in GD patient-derived fibroblasts. (A) Venn diagram of genes with 2-fold difference expression
levels in GD fibroblasts before and after sucrose treatment (upregulated and downregulated genes, red and blue sets, respectively), compared with the genes
included in the CLEAR network (471 bona fide TFEB targets, green set) and genes participating in lysosomal functions (yellow set). (B) Cytoscape-generated
network representing genes upregulated by sucrose administration. Genes (colored dots) are connected by blue lines whose color intensity is proportional to the
extent of their co-regulation. The network is organized in a core of genes with more tight expression relationships and containing an enrichment of TFEB targets
(center of the network), and in a set of genes with less tight expression relationships (periphery of the network). (C–E) GSEA of transcriptome changes follow-
ing sucrose administration to GD fibroblasts. GSEA of lysosomal genes (C), TFEB targets (D) and TFEB targets with a known role in lysosomal metabolism (E)
are reported. Upper panels show enrichment plots for each dataset, generated by GSEA of ranked gene expression data (left: upregulated, red; right:
6 Human Molecular Genetics, 2013









residual expression of TFEB) results in decrease in L444P GC
(from 3.8- to 3.3-fold in sucrose-treated cells; Supplementary
Material, Fig. S4).
Taken together, these results show that sucrose-mediated
rescue of L444P GC activity depends on TFEB concentration,
and that TFEB activation is needed to increase the activity of
wt and L444P GC.
TFEB regulates the expression of genes involved in
lysosomal targeting
Previous studies showed that modulation of the proteostasis
network to induce upregulation of GBA and enhancement of
cellular folding and trafficking result in an increase in the
amount of active GC in the lysosome, particularly in cells
expressing mutated variants otherwise prone to misfolding
and degradation (14–16). However, the overexpression of a
highly unstable GC variant such as L444P GC was shown to
be not sufficient to promote rescue of enzyme folding and ac-
tivity (9), suggesting that the innate cellular folding capacity
cannot cope with the destabilizing effect of the L444P substi-
tution. Proteostasis regulators mediate an increase in L444P
GC activity by inducing both GBA upregulation and enhance-
ment of the cellular folding capacity (14–16). We thus asked
whether cell treatment with sucrose, in addition to upregulat-
ing GC expression, also influences the expression of genes
involved in folding and trafficking through the secretory
pathway. To address this question, we treated L444P GC
Figure 4. TFEB activation mediates rescue of L444P GC activity in GD patient-derived fibroblasts. (A) Relative L444P GC activities in L444P GC fibroblasts
transfected with TFEB and treated with 150 mM sucrose for 4 days. Cell lysates were normalized to the same total protein concentration and GC activities were
normalized to the activity of untreated control sample (cells transfected with empty vector pcDNA4TM/TO) (P , 0.01). (B) Relative GC activities of wt fibro-
blasts transfected as in (A) and treated with 150 mM sucrose for 3 days. GC activities were calculated as described in (A) (P, 0.01). (C) Relative L444P GC
activities of L444P GC fibroblasts transfected with plasmids encoding wt TFEB, TFEB S142A and TFEB-NLS. GC activities were calculated as described in (A)
(P , 0.01). (D) Relative GC activities of L444P GC fibroblasts incubated with TFEB siRNA and sucrose (black bars). GC activities were normalized to the
activity measured in control cells (control siRNA) (P , 0.05). TFEB mRNA expression level was evaluated by qRT–PCR (white bars) (P , 0.05). Data are
reported as mean+SD (n ¼ 3).
downregulated, blue). The ES is shown as a blue line. Yellow shades mark the genes that have at least a 2-fold variation in treated cells compared with untreated
cells and that were used to build the Venn diagram in (A). In the middle panels, vertical blue bars indicate the position of genes in the selected gene sets within
the ranked lists. Lower panels show the cumulative distribution of gene sets within the ranked lists. The ranking positions that include 50% of analyzed genes are
indicated. The analysis shows that TFEB lysosomal targets have a higher ES score compared with general lysosomal genes or TFEB targets, indicating that
TFEB targets participating in lysosomal function were preferentially upregulated by sucrose administration in GD fibroblasts. (F) Relative mRNA expression
levels of representative genes of the CLEAR network in L444P GC fibroblasts treated with 150 mM sucrose for 2, 4 and 7 days. GBA, HEXA, TPP1, LAMP1,
ATP6V1H, GRN and PSAP mRNA expression levels were obtained by qRT–PCR, corrected by the expression of the house-keeping genes GAPDH and ACTB,
and normalized to those of untreated cells (P , 0.01). Data are reported as mean+SD (n ¼ 3).
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fibroblasts with sucrose or glycerol (150 mM, 2, 4 and 7 days)
and measured changes in the expression of representative
genes encoding proteins of the ER chaperone system [BiP
(binding immunoglobulin protein), CNX (calnexin), CRT (cal-
reticulin)], proteins involved in the UPR pathway (CHOP (C/
EBP homologous protein), ATF4 (activating transcription
factor 4)) and proteins that mediate trafficking through the se-
cretory pathway [LIMP2 (lysosomal integral membrane
protein II), M6PR (mannose-6-phosphate receptor) and
SORT1 (sortilin)]. Among genes involved in folding of secre-
tory proteins, HSPA5 (BiP) and CNX were found to be upregu-
lated by sucrose, and to a level significantly higher than
glycerol (Fig. 5A and Supplementary Material, Fig. S5).
CRT, a direct TFEB target (22), was upregulated 6.2-fold
after treatment with sucrose for 4 days, compared with
1.1-fold increase in glycerol-treated cells. ATF4 and CHOP
were mildly affected by treatment with either sucrose or gly-
cerol. These data show that sucrose treatment upregulates
the folding network in GD cells without causing activation
of the UPR, likely contributing to the rescue of L444P GC ac-
tivity.
M6PR facilitates the transport of most lysosomal hydrolases,
whereas LIMP2 and SORT1 mediate M6PR-independent trans-
port. LIMP2 was recently reported to specifically mediate
M6PR-independent transport of GC to the lysosome (25).
M6PR is a known TFEB target gene (22) and, not surprisingly,
Figure 5. TFEB activation upregulates expression of lysosomal targeting genes. (A) Relative mRNA expression levels of representative genes of the folding and
trafficking network in L444P GC fibroblasts treated with 150 mM sucrose for 2, 4 and 7 days. HSPA5 (BiP), CNX, CRT, CHOP, ATF4, LIMP2,M6PR and SORT1
mRNA expression levels were obtained by qRT–PCR, and calculated as described in Fig. 3F (P , 0.05). (B) Relative mRNA expression levels of trafficking
genes in L444P GC fibroblasts transfected with TFEB. GBA, LIMP2, M6PR, SORT1 and HGF mRNA expression levels in cells transfected with TFEB were
obtained by qRT–PCR, corrected by the expression of the house-keeping genes GAPDH and ACTB, and normalized to those of cells transfected with an
empty vector (P , 0.01). (C–F) Relative mRNA expression levels of trafficking genes in L444P GC fibroblasts upon TFEB silencing. Relative mRNA expres-
sion levels of GBA (P, 0.01) (C), LIMP2 (P , 0.01) (D), M6PR (P , 0.05) (E) and SORT1 (P, 0.05) (F) in L444P GC fibroblasts treated with TFEB siRNA
and sucrose were obtained by qRT-PCR, corrected to the expression of the house-keeping genes GAPDH and ACTB, and normalized to the activity of cells
treated with control siRNA. Data are reported as mean+SD (n ¼ 3).
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was upregulated 7.4-fold upon sucrose treatment, but not
affected by glycerol treatment (Fig. 5A and SupplementaryMa-
terial, Fig. S5). SORT1 was found to be upregulated 6-fold by
sucrose treatment but not by glycerol (Fig. 5A and Supplemen-
tary Material, Fig. S5). Interestingly, LIMP2 expression was
also dramatically increased to 7-fold after 4 days of sucrose
treatment, compared with 1.8-fold increase observed upon gly-
cerol treatment (Fig. 5A and Supplementary Material, Fig. S5).
To further evaluate whether TFEB regulates the trafficking of
lysosomal proteins through the secretory pathway, we moni-
tored the expression of M6PR, LIMP2 and SORT1 in L444P
GC fibroblasts transfected with TFEB. As shown in Fig. 5B,
the transcription ofM6PR, LIMP2 and SORT1 was upregulated
3.1-, 3.6- and 3.1-fold, respectively, upon TFEB overexpression
compared with nontransfected cells (P, 0.01). The expression
ofGC-encoding gene,GBA, a knownTFEB target (22), was also
measured for comparison and was found to be upregulated
3.9-fold (P , 0.01). The expression of the gene encoding hep-
atocyte growth factor (HGF), which is not part of the CLEAR
network (22), and is not involved in folding and trafficking of
secretory proteins was measured here as negative control and
was not altered by TFEB overexpression.
The effect of TFEB on the trafficking network was also
investigated by silencing TFEB expression. L444P GC fibro-
blasts were treated with TFEB siRNA and sucrose followed
by qRT–PCR analyses. As expected, GBA was upregulated
by sucrose treatment. However, TFEB silencing in sucrose-
treated cells lowered GBA expression (Fig. 5C). Transcriptions
of LIMP2, M6PR and SORT1 were upregulated 10.7-, 1.6-,
and 2.7-fold, respectively, in cells treated with sucrose
(Fig. 5D–F). Silencing TFEB expression decreased the ex-
pression of LIMP2, M6PR and SORT1 by 0.9-, 0.4- and
0.6-fold, respectively (Fig. 5D–F). TFEB silencing in cells
treated with sucrose also caused decrease in expression of
LIMP2, M6PR and SORT1 compared with cells only treated
with sucrose (GBA: from 9.6- to 4.7-fold, P , 0.01; LIMP2:
from 10.7- to 2.1-fold, P , 0.01; M6PR: from 1.6- to
0.5-fold, P , 0.05; SORT1: from 2.7- to 1.5-fold, P , 0.05;
Fig. 5C–F). In summary, these results confirm that TFEB reg-
ulates genes involved in lysosomal targeting and that sucrose
treatment results in TFEB-dependent upregulation of lyso-
somal trafficking.
LIMP2 mediates TFEB-dependent rescue of L444P GC
activity in GD fibroblasts
Previous studies demonstrated that LIMP2 interacts with GC
and targets it to the lysosome (25). Based on our results
showing that LIMP2 is induced by both sucrose treatment
and TFEB activation—treatments that result in rescue of GC
activity—we hypothesized that LIMP2 is a key player in
TFEB-dependent rescue of mutated GC activity in GD fibro-
blasts. To test this hypothesis, we evaluated GC activity in
L444P GC fibroblasts transfected with LIMP2 and treated
with sucrose. Overexpression of LIMP2 did not result in sig-
nificant increase in GC activity (Fig. 6A), probably due to
the severe destabilizing effect of the L444P substitution,
which results in nearly complete degradation (37). Addition
of sucrose (150 mM, 4 days) to cells transfected with LIMP2
led to a 6.0-fold increase (75% of wt GC activity; P, 0.01;
Fig. 6A), which is higher than the activity observed in cells
treated only with sucrose (4.5-fold; P, 0.01) or only for
LIMP2 overexpression.
We also measured L444P GC activity upon silencing of
LIMP2 followed by sucrose treatment. GC activity upon treat-
ment with LIMP2 siRNA was observed to decrease to 0.8-fold
compared with cells treated with a control siRNA (Fig. 6B).
LIMP2 silencing also caused a decrease in L444P GC activity
in cells treated with sucrose (from 3.2- to 1.6-fold; P, 0.01;
Fig. 6B), suggesting that LIMP2 plays a key role in sucrose-
mediated rescue of L444P GC activity.
Collectively, our results suggest that TFEB activation
results in the rescue of L444P GC activity by modulating
the CLEAR network and, particularly, by (i) inducing GBA
upregulation, and thus enhancing the pool of GC folding inter-
mediates amenable to folding rescue, (ii) inducing genes of the
folding network, thereby assisting folding of mutated GC and
favoring mutated GC ERAD escape and (iii) by inducing
LIMP2 upregulation, and thus enhancing trafficking of un-
stable L444P GC from the ER to the lysosome, where it is
highly stable due to the acidic environment for which this
enzyme was evolutionarily selected (37). To further investi-
gate this hypothesis, we tested L444P GC activity in GD fibro-
blasts treated to upregulate GC expression and to enhance the
cellular folding and trafficking capacity. Specifically, GD cells
transfected with LIMP2 were treated with proteostasis modu-
lators previously reported to upregulate GBA, enhance the
ER folding capacity and promote native folding of unstable
GC variants, namely the ERAD inhibitor, Eeyarestatin I
(16), and the proteasome inhibitor, MG-132 (12,14). Addition
of Eeyarestatin I (EerI, 6 mM) and MG-132 in cells transfected
with LIMP2 resulted in the rescue of L444P GC to 19 and 30%
of wt GC activity, respectively (P, 0.01 for both compounds;
Fig. 6C). In both the experiments, the combination of LIMP2
overexpression and treatment with a proteostasis modulator
resulted in an increase in L444P GC activity higher than
what observed using either strategy alone (e.g. LIMP2 trans-
fection and MG-132 or EerI administration). Collectively,
these results suggest that LIMP2 overexpression, by enhancing
the lysosomal trafficking capacity of GD cells, increases lyso-
somal transport of native GC that is rescued by upregulation of
ER chaperones. This proteostasis modulation approach involv-
ing upregulation of GC expression and enhancement of cellu-
lar trafficking recapitulates the features of TFEB activation
and motivates the development of chemical strategies to acti-
vate TFEB for therapeutic intervention.
Sucrose treatment enhances activity of unstable,
degradation-prone lysosomal enzyme variants in
fibroblasts derived from patients with LSDs
To test whether TFEB activation via sucrose treatment is unique
to the L444P GC variant, or more generally applicable to other
GC variants containing different destabilizing mutations, we
analyzed GD fibroblasts carrying N370S GC, which is the
most prevalent mutation found in GD patients. Fibroblasts
were treated with sucrose as described above and GC activities
were evaluated every 2 days for up to 10 days. GC activity was
observed to increase up to 39% of thewt GC activity after 4 days
of incubation (sucrose 100 mM; P, 0.01) and to 61% after 10
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days (sucrose 150 mM; P , 0.01; Fig. 7A). Interestingly, the in-
crease in residual activity observed in N370S GC fibroblasts
was less pronounced than that detected in L444PGCfibroblasts.
We attribute this difference in rescue of GC activity to the dif-
ferent destabilizing effects of the N370S and L444P substitu-
tions and the corresponding level of residual activity that
responds differently to proteostasis modulation, as previously
reported (16).
We also investigated whether sucrose treatment was able to
rescue b-hexosaminidase A (HexA) activity in fibroblasts
derived from patients with Tay–Sachs disease. Specifically,
we focused on one of the most prevalent mutations, the
G269S substitution in the HexA subunit, which destabilizes
the protein native structure causing a loss of enzymatic activ-
ity to 10% of wt HexA activity (38). Patient-derived fibro-
blasts harboring G269S HexA were cultured with sucrose
for up to 14 days and HexA activity was measured as previ-
ously described (12). Treatment with sucrose (100 mM) for 9
days led to a 2.4-fold increase in G269S HexA activity
(24% of wt HexA activity; P, 0.01; Fig. 7B). This increase
in HexA activity was still observed after 14 days of incuba-
tion, suggesting that sucrose treatment enhances native
folding, lysosomal concentration and activity of mutated
HexA.
Taken together, our data show that the activation of the
CLEAR network promotes rescue of trafficking and enzymatic
activity of degradation-prone lysosomal enzyme variants.
These results identify TFEB as a new strategic target for the
development of treatments for LSDs caused by destabilizing
missense mutations.
DISCUSSION
LSDs are a class of more than 50 inherited diseases that typ-
ically result from a defect in lysosomal function. While indi-
vidual LSDs are rare, they collectively represent one of the
most prevalent genetic disorders in children, affecting 1 of
7000 live births (39,40). Affected individuals present accumu-
lation of lysosomal substrates normally degraded by the defi-
cient enzyme and consequently enlarged lysosomes.
Dysfunction of lysosomal metabolism leads to a number of
secondary cellular processes including oxidative stress
(41,42), impaired autophagy (43) and Ca2+ homeostasis
(44,45), and ER stress (46). Multiple organ systems are
affected by the disease, due to the ubiquitous expression of
most lyososomal enzymes. As a result, the clinical signs of
LSDs can include hepatosplenomegaly, cardiac disease,
immune defects and abnormal skeletal growth (47,48). The
Figure 6. LIMP2 mediates TFEB-dependent rescue of L444P GC activity in GD patient-derived fibroblasts. (A) Relative L444P GC activities of cells overex-
pressing LIMP2 and treated with 150 mM sucrose for 4 days. GC activities were calculated as described in Fig. 4A (P , 0.01). (B) Relative L444P GC activities
of L444P GC fibroblasts treated with LIMP2 siRNA and sucrose. GC activities were calculated as described in Fig. 4D (P, 0.01). (C) Relative L444P GC
activities of cells overexpressing LIMP2 and treated with EerI (6 mM) or MG-132 (0.6 mM). GC activities were normalized to the activity of untreated cells trans-
fected with an empty vector (P , 0.05). Data are reported as mean+SD (n ¼ 3).
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most severe manifestations of these diseases affect the central
nervous system (CNS) and account for 75% of LSDs.
A number of therapeutic approaches for LSDs are being
explored. Because the majority of LSDs results from defects
in soluble lysosomal enzymes, most therapeutic strategies
aim at reconstituting soluble enzyme deficiencies either direct-
ly through enzyme replacement therapy (ERT) or indirectly
through bone marrow transplantation or gene therapy. The
safety and effectiveness of ERT have been demonstrated for
several LSDs including Gaucher, Fabry and Pompe disease
(49–51). Due to the enzyme’s short half-life and poor delivery
to certain affected areas (particularly bone and lungs), ERT
requires weekly injections and involves significant investment
of money and resources per patient for life (52). Moreover,
ERT fails to address neuronopathic symptoms due to the in-
ability of the injected enzyme to cross the blood–brain
barrier (53). Hematopoetic stem cell transplantation has also
been utilized to provide continuous source of enzyme from
hematopoetic-derived cells using either bone marrow or cord
blood. This approach, however, presents significant risks and
side effects and is typically limited to patients for whom
ERT is not available (54–57). Treatment of LSDs through
gene therapy has also been explored. A number of features
of the diseases, including modest requirement for control
over expression level—as only 5–10% of wt enzyme activity
is required to alleviate symptoms and overexpression of lyso-
somal enzymes does not seem to have detrimental effects—
single-gene defects and ubiquitous expression of lysosomal
enzymes, make LSDs good targets for gene therapy.
However, while multiple peripheral organ systems can be ef-
ficiently treated, systemic delivery of viral gene transfer
vectors has a limited effect on the CNS and direct delivery
to the CNS involves invasive procedures and limited diffusion
of the vector (58,59). In summary, currently available thera-
peutic options can sometimes ameliorate symptoms of the
disease and the quality of life of LSD patients, but fail to
repair or prevent neurodegeneration and restore function of
the CNS.
A number of highly prevalent alleles associated with LSD
development contain non-inactivating, destabilizing muta-
tions. Almost 300 unique mutations have been reported in
the gene encoding GC (GBA), with a distribution that spans
the entire gene. These include 203 missense mutations, 18
nonsense mutations, 36 small insertions or deletions that
lead to either frameshifts or in-frame alterations, 14 splice
junction mutations and 13 complex alleles carrying two or
more mutations (3). Among the 203 missense mutations char-
acterized, the first two mutations described, the L444P and
N370S substitutions (60,61) are still the most prevalent
mutant alleles encountered in most GD populations. Over
70% of the Ashkenazi Jewish patient population carries the
N370S mutation. Among non-Jewish patients, 30 and 38%
of patients carry the N370S and L444P mutation, respectively
(17). The N370S GC variant is associated with 10% of wt
activity and non-neuropathic forms of the disease (4), while
the L444P GC variant is associated with complete loss of
GC activity and, in homozygous patients, with severe neuro-
nopathic symptoms (18).
Generally speaking, non-inactivating missense mutations
are the causative variations most frequently found in LSD
patients with deficiencies in lysosomal hydrolytic activities
(62,63). Such protein variants retain function if forced to
fold into their native structure. In an attempt to provide treat-
ment options that can overcome the blood–brain barrier chal-
lenge and restore CNS functionality, efforts have been
recently focused on the development of small molecule-based
strategies aimed at rescuing folding, lysosomal trafficking and
activity of endogenous lysosomal enzyme variants. Modula-
tion of the proteostasis network has emerged as a promising
strategy to upregulate the synthesis, folding and processing
of proteins harboring destabilizing mutations and to enhance
the innate cellular capacity to maintain protein homeostasis
and sustain functions otherwise deficient in disease conditions
(12,64,65). An emerging strategy focused on lysosomal pro-
teostasis aims at identifying pathways that enhance expression
and processing of unstable, degradation-prone lysosomal
enzymes that could be targeted for the development of thera-
peutics for the treatment of LSDs. A variety of proteostasis
modulators including proteasome inhibitors (12,19), Ca2+
blockers (14,15) and ERAD inhibitors (16) enhance folding
and activity of the most destabilized GC variant containing
the L444P substitution, which is the most prevalent mutation
Figure 7. Sucrose treatment rescues lysosomal activities of mutated enzyme variants in cells derived from patients with LSDs. (A) GC activity of GD fibroblasts
carrying the N370S GC allele treated with sucrose. Relative GC activities were calculated as described in Figure 1 (P , 0.01). (B) HexA activity of Tay–
Sachs fibroblasts carrying G269S/1278insTATC HexA and cultured with sucrose. HexA activities were normalized to the activity of untreated cells
(left y-axis) (P , 0.01). The corresponding fraction of wt HexA activity is reported (right y-axis). Data are reported as mean+SD (n ¼ 3).
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in GD patients with CNS symptoms. However, given that
these proteostasis modulators are not specific for lysosomal
proteins, they are likely to have unwanted consequences on
other essential cellular pathway. Possible side effects triggered
particularly by the induction of ER stress and UPR could be
detrimental to cell function or viability and ultimately jeopard-
ize effective rescue of lysosomal proteostasis. On the other
hand, modulators of lysosomal proteostasis specific for the
lysosomal system are currently unknown.
In an attempt to identify a modulator specific to lysosomal
proteostasis, we focused on TFEB, a recently identified master
regulator of lysosomal biogenesis and function (20). TFEB
modulates lysosomal pathways by controlling the expression
of lysosomal enzymes involved in the degradation of proteins,
glycosaminoglycans, sphingolipids and glycogen (20,22).
TFEB also modulates cellular clearance by controlling autop-
hagy (24) and lysosomal exocytosis (23), which makes it a
promising target for the development of therapies for diseases
in which impaired autophagy or the storage of undegraded ma-
terial plays a role in the pathogenic cascade (23,66,67), includ-
ing LSDs (23), Huntington’s disease (20,68) and Alzheimer’s
disease (69). TFEB modulation has also been suggested to
play a role in cellular senescence (70), a process associated
with intracellular accumulation of lipofuscin. Given its mul-
tiple roles in modulating lysosomal functions, we hypothe-
sized that TFEB also regulates lysosomal proteostasis, and
used a commonly explored cellular system—fibroblasts
derived from GD patients homozygous for the highly destabi-
lized GC variant, L444P GC (4,18)—to test this hypothesis.
We report here that TFEB activation mediates rescue of
folding and lysosomal targeting of L444P GC and enhances
lysosomal GC activity in GD fibroblasts. TFEB activation
was achieved either chemically using sucrose or genetically
by transfecting GD fibroblasts with TFEB variants that local-
ize preferentially in the nucleus (TFEB S142A (24) and
TFEB-NLS-3xFLAG). Interestingly, overexpression of
TFEB resulted in partial rescue of L444P GC activity in GD
fibroblasts but did not increase GC activity in wt fibroblast
in the absence of external stimuli that promote its activation,
supporting the notion that TFEB is activated under conditions
of lysosomal impairment such as in LSDs (20). Moreover,
overexpression of wt TFEB resulted in sucrose-dependent
rescue of L444P GC activity, while overexpression of TFEB
variants that accumulate preferentially in the nucleus resulted
in an increase in L444P GC activity in the absence of sucrose
treatment, suggesting that TFEB activation mediates the
observed increase in a natively folded GC variant that loca-
lizes in the lysosome.
We found that the main transcriptional response to sucrose
administration in GD fibroblasts consisted of activation of the
CLEAR network, which is composed of various lysosome-
associated functions that are modulated by TFEB (20,22). In
particular, LIMP2, a gene involved in lysosomal targeting of
GC (25), was dramatically upregulated by sucrose treatment
as well as upon genetic activation of TFEB and was found
to play a critical role in TFEB-mediated rescue of GC
folding and activity. Our results indicate that the rescue of
folding and lysosomal targeting of this highly unstable
variant is dependent on simultaneous upregulation of GBA
transcription (which enhances the pool of unstable GC
amenable to folding rescue), and enhancement of the cellular
folding and trafficking capacity. In summary, rescue of
L444P GC activity was promoted by TFEB-mediated induc-
tion of genes encoding lysosomal proteins and accessory pro-
teins needed for their processing.
Single-residue substitutions are the most common causative
variations encountered in LSD patients with deficiencies in
lysosomal enzyme activities (62,63). Interestingly, TFEB acti-
vation was also found to enhance activity of a distinct GC
variant—N370S GC, the most prevalent mutant among GD
patients—and of a mutated HexA variant associated with the
development of Tay–Sachs disease. While these results
confirm the role of TFEB as a modulator of lysosomal proteos-
tasis, additional studies are needed to prove generality of this
strategy for the treatment of other LSDs characterized by mis-
folding, non-inactivating mutations in lysosomal enzymes.
In summary, we provided evidence that TFEB activation
mediates rescue of unstable, degradation prone lysosomal
enzyme variants by simultaneously upregulating their tran-
scription and enhancing the cellular trafficking capacity, thus
facilitating processing of proteins that traverse the secretory
pathway. Our findings demonstrate a new role of TFEB in
regulating lysosomal proteostasis and suggest TFEB as a can-
didate therapeutic target to rescue enzyme homeostasis in
LSDs.
MATERIALS AND METHODS
Reagents, plasmids and cell cultures
Sucrose was purchased from Calbiochem. Glycerol was pur-
chased from Acros Organics. Eeyarestatin I was obtained
from ChemBridge. MG-132 was obtained from Cayman
Chemical. Lacidipine and conduritol B epoxide (CBE) were
from Toronto Research Chemicals. 4-Methylumbelliferyl
b-D-glucoside (MUG) was obtained from Sigma-Aldrich.
Cell culture media were obtained from Lonza.
GD patient-derived fibroblasts homozygous for the L444P
(1448T . C) mutation (GM10915) were obtained from
Coriell Cell Repositories. Fibroblasts were grown at 378C in
5% CO2 in minimal essential medium with Earle’s salts, sup-
plemented with 10% heat-inactivated fetal bovine serum and
1% glutamine Pen-Strep. Medium was replaced every 3 or 4
days. Monolayers were passaged with TrypLE Express.
The TFEB-NLS-3 × FLAG plasmid was obtained by muta-
genesis of the TFEB-3xFLAG plasmid using QuikChangew II
XL site-directed mutagenesis kit and a reverse primer that con-
tained the NLS coding sequence, 5′-CCAAAGAAGAAGCG-
TAAG-3′ (71,72), just downstream of the last TFEB coding
codon. The correct insertion of the NLS coding sequence was
verified by sequencing, and the localization of the
TFEB-NLS-3 × FLAGprotein product was determined by con-
focal microscopy analysis.
Enzyme activity assays
The intact cell GC activity assay was performed as previously
described (12). Briefly, 100 ml aliquots of 104 cells were
plated in each well of a 96-well plate and incubated overnight
to allow cell attachment. The medium was replaced with fresh
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medium containing small molecules (small molecule concen-
trations and time of incubation are specified in each experiment)
and plates were incubated at 378C. The medium was then
aspirated and cells were washed with PBS three times. The
assay reaction was started by the addition of 50 ml of 2.5 mM
4-MUG in 0.2 M acetate buffer (pH 4.0) and stopped after 7 h
of incubation at 378C by the addition of 150 ml of 0.2 M
glycine buffer (pH 10.8) to each well. Liberated 4-
methylumbelliferone was measured (excitation 365 nm, emis-
sion 445 nm) with a SpectraMax Gemini plate reader (Molecu-
lar Device). Non-lysosomal GC activity was evaluated by
measuring GC activities in the presence of Conduritol B
Epoxide (CBE) at 1 mM final concentration. Relative GC activ-
ities were calculated by subtracting the background of non-
lysosomal activity and normalizing the obtained values by the
activity of untreated cells.
The lysed cell GC activity assay was performed as previous-
ly described (13). Briefly, the cells were collected and lysated
with the complete lysis-M buffer containing the protease in-
hibitor cocktail (Roche). Total protein concentrations were
determined by the Bradford assay (Thermo Scientific) and
each sample was diluted to the same protein concentration.
The assay was performed by adding 50 ml of 2.5 mM MUG
in 0.2 M acetate buffer (pH 4.0) containing 0.15% Triton
X-100 (v/v, Fisher) and 0.15% taurodeoxycholate (w/v, Cal-
biochem) to 10 ml aliquots of cell lysates. The assay reaction
was stopped by the addition of 150 ml of 0.2 M glycine buffer
(pH 10.8) to each well after 7 h of incubation at 378C. Liber-
ated 4-methylumbelliferone was measured (excitation 365 nm,
emission 445 nm) with a SpectraMax Gemini plate reader
(Molecular Device). CBE at 2 mM final concentration was
used as a control to evaluate non-lysosomal GC activity. Rela-
tive GC activities were calculated by subtracting the back-
ground of non-lysosomal activity and normalizing the
obtained values by the activity of untreated cells. Fold
changes in GC activity were then corrected by TFEB mRNA
expression level (evaluated by qRT-PCR) in cells transfected
with TFEB.
b-hexosaminidase A (HexA) activity assay was performed
as described previously (12,16).
Western blot analysis
Cells were incubated with sucrose for 4 days, collected and
lysated with the complete lysis-M buffer containing the prote-
ase inhibitor cocktail (Roche). Total protein concentrations
were determined by the Bradford assay (Thermo Scientific)
and each sample was diluted to the same protein concentra-
tion. Treatment with endoglycosidase H (EndoH) was per-
formed by incubating samples at 958C for 10 min, followed
by incubation with EndoH (New England Biolabs) for 1 h at
378C. Aliquots of cell lysates were separated by 10% SDS–
PAGE gel. Western blot analyses were performed using
primary antibodies (rabbit anti-GC (Sigma-Aldrich), or
rabbit anti-GAPDH (Santa Cruz Biotechnology)) and
HRP-conjugated goat anti-rabbit (Santa Cruz Biotechnology)
as the secondary antibody. Blots were visualized using a
Luminata Forte Western HRP substrate (Millipore) and quan-
tified by NIH ImageJ analysis software.
Immunofluorescence
Fibroblasts were seeded on glass coverslips, cultured in the
presence of sucrose for 4 days and fixed with 4% paraformal-
dehyde for 30 min. Cells were permeabilized with 0.1%
Triton-X for 5 min and incubated with 8% bovine serum
albumin for 1 h. Following incubation for 1 h with primary
antibodies (rabbit anti-b-GC and mouse anti-CNX antibodies,
Sigma-Aldrich), the cells were washed three times with 0.1%
Tween-20/PBS, and then incubated with secondary antibodies
for 1 h (Dylight 488 goat anti-mouse IgG and Dylight 549 goat
anti-rabbit IgG from KPL, and FITC anti-LAMP1 from Biole-
gend). Images were obtained using an Olympus IX81 confocal
microscope and co-localized using the Fluoview software.
Co-localization heatmap images were analyzed using NIH
ImageJ analysis software.
Microarray experiments
Total RNA from GD fibroblasts before and after treatment
with sucrose (100 mM, 4 days) was used to prepare cDNA
for hybridization to the Illumina Human HT-12 V4.0 array
platform. Hybridizations were performed in triplicates at the
Microarray Core and Cell and Regulatory Biology, University
of Texas, Houston, TX, USA. A P-value of ,0.01 was used to
assess significant gene differential expressions. Gene set en-
richment analysis was performed as previously described
(35). The cumulative distribution function was constructed
by performing 1000 random gene set membership assign-
ments. A nominal P-value of ,0.01 and an FDR of ,10%
were used to assess the significance of the enrichment score
(ES). GO analyses were performed with the web tool
DAVID (73) using default parameters. Redundant terms
were manually removed from the resulting lists. Pathway
co-expression analyses were performed as previously
described (22,33) and the expression correlation data were
analyzed with Cytoscape (34) to draw a visual representation
of relationships among co-expressed genes.
Quantitative RT-PCR
qRT–PCR was performed as previously described (16). Cells
were incubated with small molecules for indicated time
lengths before total RNA was extracted using RNAGEM
TM
reagent (ZyGEM). Complementary DNA (cDNA) was synthe-
sized from total RNA using qScriptTM cDNA SuperMix
(Quanta Biosciences). Total cDNA amount was measured by
NanoDrop 2000 (Thermo Scientific). qRT–PCR reactions
were performed using cDNA, PerfeCTaTM SYBR Green Fas-
tMixTM (Quanta Biosciences) and the corresponding primers
(Supplementary Material, Table S2) in the CFX96TM real-time
PCR detection system (Bio-Rad). Samples were heated for
2 min at 958C and amplified in 45 cycles for 1 s at 958C,
30 s at 608C and 30 s at 728C. Analyses were conducted
using CFX manager software (Bio-Rad) and the threshold
cycle (CT) was extracted from the PCR amplification plot.
The DCT value was calculated as previously described (74)
to normalize the CT of each target gene to that of the
house-keeping genes GAPDH and ACTB. The relative
mRNA expression level of each target gene in treated cells
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was normalized to that measured in untreated cells: relative
mRNA expression level ¼ 2[2(DCT (treated cells)2DCT (untreated
cells))]. Each data point was evaluated in triplicate and mea-
sured three times.
Cell transfection
Transfection procedures were performed as follows: 106 cells
in 10 ml of growth medium were plated in a 10 cm culture
dish and incubated overnight to allow cell attachment. Trans-
fection reactions were conducted using jetPRIMETM reagent
(Polyplus Transfection) when cells reached 80% confluency.
After 16 h incubation, the transfection medium was replaced
by fresh medium or medium containing 150 mM sucrose.
Lysosomal GC activities were measured using the lysed cell
GC activity assays. GC activities were corrected for TFEB ex-
pression level (evaluated by qRT-PCR) to eliminate differ-
ences in enzymatic activities due to variability of
transfection efficiency.
siRNA transfection
siRNA transfection was performed using HiPerFectw transfec-
tion reagent (Qiagen). Each well of a 96-well plate was spotted
with 12.5 ng siRNA in 3 ml RNase-free water. 0.75 ml of
HiPerFect transfection reagent was diluted with 24.25 ml of
serum-free culture medium and added to each well. The
mixture was incubated for 10 min at RT to allow formation
of transfection complexes. 104 cells in 175 ml of culture
medium were seeded into each well on top of the transfection
complexes and incubated for 2 days. The medium was
replaced by medium or medium containing 150 mM sucrose.
Lysosomal GC activities were measured after 3 days by
intact cell GC activity assays. TFEB siRNA (Cat. No.
SI00094969), LIMP2 siRNA (Cat. No. SI02777215) and
control siRNA (Cat. No.1027280) were purchased from
Qiagen. ON-TARGETplus Human TFEB siRNA (Cat. No.
L-009798-00-0010) was purchased from Thermo Scientific.
Toxicity assay
Toxicity assay was conducted as previously described (16).
Briefly, the cells were collected after incubating with small
molecules for 24 h. Cell toxicity was tested using the
CytoGLO
TM
Annexin V-FITC apoptosis detection kit
(IMGENEX) according to the manufacturer’s instructions
and analyzed by flow cytometry (FACSCanto
TM
II, Beckon
Dickingson) with a 488 nm argon laser.
Statistical analysis
All data are presented as mean+SD, and statistical signifi-
cance was calculated using a two-tailed t-test.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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